Categories LATEST

Is Advaxis exhausting its financial resources with the stock hitting a record low?

Advaxis Inc. (NASDAQ: ADXS) stock plunged to a record low of $1.54 on Tuesday as the late-stage biotech company has returned the prepayments it received from customers due to the termination of a contract. Also, investors were unsatisfied with the company’s performance during the second quarter and its strategy in exhausting its financial resources.

Advaxis has depended on the protection of its intellectual property and it currently owns or have rights to over 400 patents and applications. The company has a history of losses and that will continue throughout its clinical stage. Advaxis is likely to exhaust its financial resources and be unable to complete the development of its products.

The company anticipates that its ongoing operational costs will increase significantly as it continues conducting its clinical development program. The company’s deficit will continue to grow during its drug development period.

pharma stocks
Image Courtesy: Louis Reed/Unsplash

Advaxis expects losses to continue for the foreseeable future due to its substantial investment in research and development. As of April 30, 2019, the company had an accumulated deficit of about $364.22 million and stockholders’ equity of about $43.17 million.

The company expects to spend substantial additional sums on the continued administration and research and development of proprietary products and technologies with no certainty that its immunotherapies will become commercially viable or profitable as a result of these expenditures.

Investors were cautious that the company could significantly curtail operations or cease operations in the near future if failing to raise significant capital. Also, the profitability remained not achievable if the product candidates fail in clinical trials or do not gain regulatory approval. Also, the company doesn’t have adequate resources in sustaining profitability in subsequent periods after achieving profits once.

Also read: Will Boeing 737 Max take off again this year

During the second quarter, the company has experienced nil deferred or unearned revenue for the most recent quarter. This denoted that the company hasn’t received any new orders from any customers and it has returned the prepayments due to termination of a contract. Along with a decline in the liabilities, the company shredded out cash in closing its short-term debt.

Shares of Advaxis opened lower on Tuesday and is trading in the red territory on the Nasdaq. The stock has fallen over 93% in the past year and over 60% in the past three months. The 50-day moving average stood at $2.48 while the 200-day moving average remained at $4.25.

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

V Earnings: Key quarterly highlights from Visa’s Q1 2023 financial results

Visa Inc. (NYSE: V) reported first quarter 2023 earnings results today. Net revenues grew 12% year-over-year to $7.9 billion. GAAP net income rose 6% to $4.2 billion while EPS grew

Earnings: Highlights of Intel’s (INTC) Q4 2022 financial results

Intel Corporation (NASDAQ: INTC) Thursday reported a decline in adjusted earnings and revenues for the fourth quarter. The semiconductor giant also provided guidance for the first quarter of 2023. Fourth-quarter

McCormick (MKC) expects to drive sales growth in 2023 through pricing actions and cost savings

Shares of McCormick & Company Inc. (NYSE: MKC) were down over 5% on Thursday after the company missed expectations on its fourth quarter 2022 results and provided a lower-than-expected earnings

Add Comment
Viewing Highlight